AI neuroimaging tools dazzle in the lab but stall before the operating room, review finds

Artificial intelligence can now segment a brain tumor, flag a hemorrhage on a CT scan, and trace the white-matter highways a surgeon must avoid, all in seconds. Yet according to a narrative review published in BMC Artificial Intelligence, almost none of these tools have made the journey from the computer screen to the operating table. The review, led by Godswill Uzoechina and Treasure Osajiuba, examined literature published between 2015 and 2025 and concluded that AI neuroimaging is technically mature but clinically under-validated, with the majority of studies remaining retrospective, single-center, and lacking external validation.

The numbers behind the enthusiasm are real. Tumor segmentation models built on 3D U-Net architectures achieve Dice scores of roughly 0.80 to 0.90 in BraTS challenge-based evaluations and selected external validation cohorts. Hemorrhage detection networks report sensitivities above 90 percent and areas under the curve near 0.95 in retrospective datasets. Tractography augmented by constrained spherical deconvolution outperforms simple diffusion tensor imaging for mapping motor tracts before surgery, and augmented reality overlays are increasingly feasible in controlled settings. The review’s authors do not dispute these benchmarks. What they dispute is what the benchmarks mean for a patient on the table.

The answer, they argue, is far less than the raw scores suggest. Most of the evidence reflects algorithm-only retrospective validation, with limited prospective deployment or clinician-in-the-loop evaluation. The DeepBleed intracranial hemorrhage segmentation model illustrates the pattern: it posted high internal Dice scores, showed modest performance degradation in multicenter evaluation, and required site-specific retraining or calibration to preserve accuracy across practices. Models trained on homogeneous datasets risk overfitting to local scanner artifacts, anatomical variability, or demographic distributions, and domain shift can silently degrade performance in ways that mislead surgical planning rather than merely lowering a metric.

Scanner heterogeneity is only one hazard. Deep models can unintentionally learn to predict sensitive demographic factors such as self-reported race and ethnicity from medical images, meaning latent confounders can propagate decision-making bias unless explicitly assessed. Motion, metal implants, and surgical instruments introduce artifacts that deteriorate model performance, and even training that includes artifact-containing images cannot guard against rare artifact patterns producing unexpected errors. The review also notes that many cleared AI-enabled devices entered the market with limited prospective clinical evaluation, a regulatory reality that compounds the technical one.

Explainability has been proposed as the bridge between algorithmic output and clinical trust, and the review devotes sustained attention to it. Common techniques include saliency and attention maps, feature importance rankings, and counterfactual reasoning. But the authors caution that saliency-based approaches are unstable under small input perturbations and may highlight non-causal regions, raising the risk that surgeons overinterpret visually salient but clinically irrelevant areas. Attention maps can encourage cognitive bias, in which surgeons rely disproportionately on AI suggestions without further interrogation. Current evidence remains limited on whether explainability actually improves objective decision accuracy rather than subjective confidence.

Human factors compound the uncertainty. Automation bias and overtrust are particular concerns in high-stakes neurosurgical environments, where an authoritative-looking output may mask uncertainty or model limitations. Pilot studies of augmented reality overlays during tumor resections report that well-calibrated, contextually integrated visualizations decrease cognitive load and aid spatial orientation, while poorly calibrated or opaque overlays increase cognitive effort and hesitation. The review frames explainability as a useful adjunct to clinical judgment, not a replacement for it, and recommends interactive interfaces, adjustable transparency settings, and confidence indicators so surgeons can verify outputs rather than accept them.

Tools must interoperate with DICOM imaging standards, picture archiving systems, and surgical navigation platforms, or they risk becoming siloed. Latency is a hard constraint: studies suggest acceptable intraoperative latency is two seconds or less, beyond which surgeons report diminished usability and trust. Meeting that threshold requires edge computing in the operating room, GPU-powered consoles, or cloud models with local caching, each with trade-offs in speed, cybersecurity, and maintenance. Registration accuracy must reach sub-millimeter precision, and validation typically involves phantom studies, cadaveric models, or comparisons against neuronavigation landmarks before widespread use.

The regulatory landscape adds further friction. The FDA and EMA regulate AI imaging software as Software as a Medical Device, but as of 2025 only a very small percentage of AI neuroimaging tools have received full FDA or CE approval, mostly for stroke triage or hemorrhage detection. Tumor segmentation and AR-assisted navigation remain investigational. Continuous-learning systems face a particular bottleneck, since initial approval covers locked algorithms while adaptive retraining requires pre-specified change protocols under emerging frameworks such as the FDA’s Predetermined Change Control Plan. Liability questions remain unresolved: if an AI-generated overlay misguides a resection, responsibility currently rests with the clinician, though calls for shared accountability frameworks are rising.

Economics and bias round out the obstacles. Hidden costs include GPU hardware, cybersecurity infrastructure, vendor licensing, and personnel for updates and local validation, and hospitals adopting AI navigation or AR systems have reported training periods of six to twelve months before consistent, safe use. Reimbursement is unsettled, with some stroke detection software holding unique CPT codes while most neurosurgical applications lack defined codes. Many models are trained predominantly on Western, high-resource populations, risking systematic underperformance in underrepresented groups, and initiatives such as TRIPOD-AI and CONSORT-AI are cited as essential for transparent reporting of training cohorts.

The review’s conclusion is measured rather than dismissive. AI neuroimaging has clear potential to improve the accuracy and efficiency of neurosurgical care, and the authors propose a structured framework connecting validation, explainability, and implementation so departments can judge which tools are genuinely ready. Their recommended pathway moves from pre-purchase assessment of external validation and regulatory approval, through local validation against expert annotations, simulator-based training, and staged rollout beginning with low-risk adjunctive uses, to ongoing surveillance of errors and patient outcomes. But they are explicit that demonstration of direct effects on clinical decision-making, surgical outcomes, or patient morbidity is limited, and that current benefits are largely inferred from improved accuracy or efficiency rather than validated through prospective clinical endpoints. Until robust multicenter trials, transparent explainability, and genuine workflow integration arrive together, the distance from image to incision remains the field’s most stubborn gap.

Subject of Research: Clinical validation, explainability, and workflow integration of AI neuroimaging tools for neurosurgical decision support

Article Title: From image to incision: clinical validation, explainability, and workflow integration of AI neuroimaging tools for real-time neurosurgical decision support

Article References: Uzoechina, G., & Osajiuba, T. (2026). From image to incision: clinical validation, explainability, and workflow integration of AI neuroimaging tools for real-time neurosurgical decision support. BMC Artificial Intelligence, 2(1), Article 16. https://doi.org/10.1186/s44398-026-00035-8

Image Credits: AI Generated

DOI: 10.1186/s44398-026-00035-8

Keywords: artificial intelligence, neurosurgery, neuroimaging, clinical validation, explainability, workflow integration, tumor segmentation, hemorrhage detection, augmented reality, regulatory approval, automation bias, multicenter trials